Premium
Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia
Author(s) -
Fredman P.,
Wallin A.,
Blennow K.,
Davidsson P.,
Gottfries CG.,
Svennerholm L.
Publication year - 1992
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1992.tb04006.x
Subject(s) - cerebrospinal fluid , vascular dementia , dementia , medicine , glycosphingolipid , myelin , alzheimer's disease , endocrinology , gastroenterology , pathology , disease , central nervous system , biology , biochemistry
The myelin‐associated glycosphingolipid sulfatide in cerebrospinal fluid (CSF) was investigated in 20 patients with vascular dementia (VAD), 43 with Alzheimer's disease (AD) and 20 age‐matched controls. The sulfatide concentration in the VAD group (307 ± 118 nmol/l) was significantly (p < 0.0001) higher than that in controls (145 ± 86 nmol/l) and the AD group (178 ± 79 nmol/l). Among the VAD patients, 8/20 had a significantly increased concentration of sulfatide (>mean + 2 S.D.), as compared with controls, while only 2/43 of the AD patients had a sulfatide concentration above this level. It is suggested that the elevated concentration of sulfatide in CSF from VAD patients reflects demyelination. Furthermore, sulfatide determinations, when combined with clinical findings, may be of diagnostic value, for discriminating between VAD and AD.